Martin Uhl
Universitätsklinikum Erlangen(DE)
Publications by Year
Research Areas
Glioma Diagnosis and Treatment, Brain Metastases and Treatment, TGF-β signaling in diseases, Metabolism, Diabetes, and Cancer, Multiple Sclerosis Research Studies
Most-Cited Works
- → Activation of the NLRP3 inflammasome in dendritic cells induces IL-1β–dependent adaptive immunity against tumors(2009)1,805 cited
- → Lomustine-temozolomide combination therapy versus standard temozolomide therapy in patients with newly diagnosed glioblastoma with methylated MGMT promoter (CeTeG/NOA–09): a randomised, open-label, phase 3 trial(2019)568 cited
- → SD-208, a Novel Transforming Growth Factor β Receptor I Kinase Inhibitor, Inhibits Growth and Invasiveness and Enhances Immunogenicity of Murine and Human Glioma CellsIn vitroandIn vivo(2004)411 cited
- → Bevacizumab Plus Irinotecan Versus Temozolomide in Newly Diagnosed O6-Methylguanine–DNA Methyltransferase Nonmethylated Glioblastoma: The Randomized GLARIUS Trial(2016)195 cited
- → Autophagy within the antigen donor cell facilitates efficient antigen cross-priming of virus-specific CD8+ T cells(2009)187 cited
- → NOA‐03 trial of high‐dose methotrexate in primary central nervous system lymphoma: Final report(2005)185 cited
- → Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma model(2007)94 cited
- → Migratory neural stem cells for improved thymidine kinase-based gene therapy of malignant gliomas(2005)56 cited
- → Antigen Persistence Is Required for Dendritic Cell Licensing and CD8+ T Cell Cross-Priming(2008)45 cited
- → Health-related quality of life and neurocognitive functioning with lomustine–temozolomide versus temozolomide in patients with newly diagnosed, MGMT-methylated glioblastoma (CeTeG/NOA-09): a randomised, multicentre, open-label, phase 3 trial(2019)43 cited